1. Acknowledgement to Referees

   Acknowledgement to Referees 10 November 2020 Pages: 701 - 704

2. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?

   • Shubham Atal
   • Zeenat Fatima
   • Sadasivam Balakrishnan

   Current Opinion 13 October 2020 Pages: 705 - 711

3. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease

   • Ahmed Almradi
   • Jurij Hanzel
   • Vipul Jairath

   Leading Article 26 October 2020 Pages: 713 - 721

   

4. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?

   • Daniel F. Alvarez
   • Gertjan Wolbink
   • Jonathan Kay

   Review Article Open access 29 September 2020 Pages: 723 - 732

   

5. The Immunotherapy Landscape in Renal Cell Carcinoma

   • Landon C. Brown
   • Kunal Desai
   • Moshe C. Ornstein

   Review Article 13 October 2020 Pages: 733 - 748

6. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?

   • Tarek Taha
   • Ari Reiss
   • Ruth Perets

   Review Article 03 November 2020 Pages: 749 - 762

7. Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration

   • Paula I. Fuller-Carter
   • Hamed Basiri
   • Livia S. Carvalho

   Review Article 02 November 2020 Pages: 763 - 781

8. European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption

   • Liese Barbier
   • Steven Simoens
   • Isabelle Huys

   Original Research Article Open access 03 November 2020 Pages: 783 - 796

   

9. European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice

   • Liese Barbier
   • Steven Simoens
   • Isabelle Huys

   Original Research Article Open access 15 October 2020 Pages: 797 - 808

   

10. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

    • Piotr Wiland
    • Sławomir Jeka
    • Norman B. Gaylis

    Original Research Article Open access 29 October 2020 Pages: 809 - 823